) The broad, long-term objective of this proposal is to develop photodynamic therapy as a local treatment for patients with prostate cancer.
The Specific aims are: (1) to determine the doselimiting toxicities and maximally tolerated dose of Lutetium texaphyrin-mediated photodynamic therapy (PDT) in patients with recurrent prostate cancer, (2) to make direct tissue measurements of Lutetium texaphyrin in biopsies of the prostate before and after PDT, and (3) to measure Lutetiurn texaphryin levels in the prostate with in situ fluorescent (optical) methods and to compare these results with direct tissue measurements. The research design is a Phase I, dose escalation clinical trial of PDT using Lutetium texaphyrin and 730 nm light in patients with recurrent prostate cancer who have failed radiotherapy. Lutetium texaphyrin will be given intravenously prior to light delivery. Light delivery will be achieved using fibers inserted interstitially via a perineal template in the operating room and the dose will be monitored using an on-line dosimetry system. Direct measurements of Lutetium texaphyrin will be made in prostate biopsy specimens using tissue fluorescence and high pressure liquid chromatography.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA088064-02
Application #
6378128
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J2))
Program Officer
Stone, Helen B
Project Start
2000-06-01
Project End
2003-05-31
Budget Start
2001-06-01
Budget End
2003-05-31
Support Year
2
Fiscal Year
2001
Total Cost
$287,731
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Du, K L; Mick, R; Busch, T M et al. (2006) Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med 38:427-34
Verigos, Kosmas; Stripp, Diana C Hsiung; Mick, Rosemarie et al. (2006) Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 25:373-87
Yu, Guoqiang; Durduran, Turgut; Zhou, Chao et al. (2006) Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol 82:1279-84
Altschuler, Martin D; Zhu, Timothy C; Li, Jun et al. (2005) Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. Med Phys 32:3524-36
Zhu, Timothy C; Finlay, Jarod C; Hahn, Stephen M (2005) Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B 79:231-41
Zhu, Timothy C; Dimofte, Andreea; Finlay, Jarod C et al. (2005) Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol 81:96-105